Scholarlink

<p>This study investigates the role of extracellular vesicles (EVs) in predicting melanoma patients’ responses to anti-PD1 immunotherapy. Nine patients with advanced melanoma provided blood samples at three stages: before treatment, before the second dose, and either at disease progression or nine months later. EVs were isolated from serum and analyzed using mass-spectrometry proteomics, followed by network and enrichment analyses. Six out of nine patients progressed despite treatment. Before therapy, responders exhibited higher levels of adaptive immune and cell adhesion proteins, while proteins related to UV radiation response were deplected. An eight-protein signature and cellular adhesion markers correlated with longer progression-free survival. After treatment, non-responders had EV proteins enriched in proteasome activity and metabolic pathways, especially glycolysis. Finally, dynamic changes in EV protein over time showed decreased coagulation proteins, along with an increase in MHC proteins in patients with progressive disease. Overall, EV protein profiles differed between responders and non-responders both before and during therapy. These findings suggest that EVs could provide predictive biomarkers and insights into resistance mechanisms, potentially guiding more effective melanoma treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Protein content of extracellular vesicles from patients with advanced melanoma changes upon progression to anti-PD1 therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月21日

查看全文
  • Lucía Trilla-Fuertes,
  • Angelo Gámez-Pozo,
  • Fernando Laso-García,
  • Gema Maqueda,
  • Fernando Becerril-Gómez,
  • Lorena Sánchez,
  • Mariana Díaz-Almirón,
  • Pedro Lalanda-Delgado,
  • Ana García-Carneros,
  • Rocío López-Vacas,
  • María Beato,
  • Bernd Roschitzki,
  • María Gutiérrez-Fernández,
  • Paolo Nanni,
  • Juan Ángel Fresno Vara,
  • Enrique Espinosa

摘要

This study investigates the role of extracellular vesicles (EVs) in predicting melanoma patients’ responses to anti-PD1 immunotherapy. Nine patients with advanced melanoma provided blood samples at three stages: before treatment, before the second dose, and either at disease progression or nine months later. EVs were isolated from serum and analyzed using mass-spectrometry proteomics, followed by network and enrichment analyses. Six out of nine patients progressed despite treatment. Before therapy, responders exhibited higher levels of adaptive immune and cell adhesion proteins, while proteins related to UV radiation response were deplected. An eight-protein signature and cellular adhesion markers correlated with longer progression-free survival. After treatment, non-responders had EV proteins enriched in proteasome activity and metabolic pathways, especially glycolysis. Finally, dynamic changes in EV protein over time showed decreased coagulation proteins, along with an increase in MHC proteins in patients with progressive disease. Overall, EV protein profiles differed between responders and non-responders both before and during therapy. These findings suggest that EVs could provide predictive biomarkers and insights into resistance mechanisms, potentially guiding more effective melanoma treatment strategies.